DrDraganaMilojkovic

Maynard S, Ros-Soto J, Chaidos A, et al.Maynard S, Ros-Soto J, Chaidos A, Innes A, Paleja K, Mirvis E, Buti N, Sharp H, Palanicawandar R, Milojkovic D close, 2021, The role of ibrutinib in COVID-19 hyperinflammation: a case report, International Journal of Infectious Diseases, Vol:105, ISSN:1201-9712, Pages:274-276

• DOI
• Publisher Web Link
• Open Access Link

Claudiani S, Apperley JF, Deplano S, et al.Claudiani S, Apperley JF, Deplano S, Khorashad J, Foroni L, Palanicawandar R, Perry R, Milojkovic D close, 2016, Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia, American Journal of Hematology, Vol:91, ISSN:1096-8652, Pages:E480-E481

• DOI
• Open Access Link

Neelakantan P, Rezvani K, May P, et al.Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic D close, 2014, Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects, British Journal of Haematology, Vol:164, ISSN:0007-1048, Pages:608-610

• DOI
• Author Web Link

Milojkovic D, Apperley J, 2008, State-of-the-art in the treatment of chronic myeloid leukaemia, Current Opinion in Oncology, Vol:20, ISSN:1040-8746, Pages:112-121

• DOI
• Author Web Link

De Melo VA, Milojkovic D, Khorashad JS, et al.De Melo VA, Milojkovic D, Khorashad JS, Marin D, Goldman JM, Apperley JF, Reid AG close, 2007, Philadelphia-negative clonal haematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukaemia, Blood, Vol:110, Pages:3086-3087